Trial Profile
TevaGastrim for Stem Cell Mobilization of HLA Matched Sibling Donors for Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- 19 Apr 2016 Status changed from active, no longer recruiting to completed.
- 01 Dec 2015 Planned End Date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov record.
- 01 Dec 2015 Planned primary completion date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov record.